化合物COH29 T3157

Product Introduction
Bioactivity


英文名: COH29

描述: COH29 (RNR Inhibitor COH29) 是一种口服可用的芳香族取代噻唑，是人类核糖核苷酸还原酶 (RNR) 的抑制剂，具有潜在的抗肿瘤活性。它抑制核糖核苷酸还原酶的IC50为 16 μM。

细胞实验: Cells is seeded into 96-well plates in 100 μL of complete medium at 2000 to 5000 cells per well, depending on the cell line's growth rate. After overnight incubation, test compound is added to each well at various concentrations in 50 μL of culture medium. After a further incubation for 96 hours at 37°C, fluorescein diacetate (final concentration: 10 mg/mL) and eosin Y [final concentration: 0.1% (w/v)] is added to each well, and the cells is incubated for an additional 20 minutes at 37°C. Cytotoxicity is assessed by Digital Imaging Microscopy System detection Viability is assessed using MTS [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)] as previously described[1].

激酶实验: For kinase assays following immunoprecipitation of FLAG-CDK7 protein from HCT116 or FLAG-CDK12 from 293A cellular lysates, cells are first treated with THZ1, THZ1-R, or DMSO for 4 hrs at 37°C. Cells are then harvested by lysis in 50 mM Tris HCl pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA, and protease/phosphatase cocktails. Exogenous CDK7 or CDK12 proteins are immunoprecipitated from cellular lysates using FLAG antibody- conjugated agarose beads. Precipitated proteins are washed with lysis buffer 6 times, followed by 2 washes with kinase buffer (40 mM Hepes pH 7.5, 150 mM NaCl, 10 mM MgCl2, 5% glycerol) and subjected to in vitro kinase assays at 30°C for 45 minutes using 1 μg of the large subunit of RNAPII (RPB1) as substrate and 25 μM ATP and 10 μCi of 32P ATP. Kinase assays using recombinant CDK7/TFIIH/MAT1 are conducted in the manner as described above using 25 ng of CAK complex per reaction. For kinase assays designed to test time-dependent inactivation of CDK7 kinase activity, CAK complex is pre-incubated with indicated concentrations of THZ1, THZ1-R, or DMSO in kinase buffer without ATP for 4 hrs at 30°C prior to being subjected to kinase assay conditions[1].

体外活性: COH29 overcome gemcitabine and hydroxyurea resistance in Y cells. It potently inhibits proliferation of most cell lines in the NCI 60 human Y panel, most especially leukemia and ovarian Y, but exerts little effect on normal fibroblasts or endothelial cells. NMR, site-directed mutagenesis, and surface plasmon resonance biosensor studies confirm COH29 binding to the proposed ligand-binding pocket and offer evidence for assembly blockade of the RRM1-RRM2 quaternary structure[1].

体内活性: COH29 (50/100 mg/kg, b.i.d., p.o.)results in a dose-dependent inhibition of MOLT-4 tumor xenograft growth, which is pronounced by Day 12 of treatment. In mice bearing TOV11D xenografts, 7 days of treatment with COH29 (200/300/400 mg/kg/day) results in a dose-dependent inhibition of tumor xenograft growth. Compared with the control group, tumor growth is significantly inhibited [1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (118.92 mM)


关键字: ribonucleotide | RNR | inhibit | reductase | DNA/RNA Synthesis | RNR Inhibitor COH-29 | subunit | RNR Inhibitor COH 29 | COH-29 | Inhibitor | COH 29 | COH29 | anticancer

相关产品: BCH001 | SR 11302 | GS-443902 | L189 | ddTTP trisodium | 5-methoxyflavone | SMN-C3 | L67 | Pritelivir | Thymidine

相关库: Anti-Aging Compound Library | Drug Repurposing Compound Library | Cell Cycle Compound Library | Anti-Cancer Drug Library | Bioactive Compounds Library Max | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Active Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library

化合物COH29 T3157信息由TargetMol中国为您提供，如您想了解更多关于化合物COH29 T3157报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途